Our lead technology consists of non-phagocytosable MPs designed to ensure the sustained release of select tolerogenic agents to create a tolerogenic microenvironment at the site of a subcutaneous injection. Phagocytosable MPs containing auto-antigen and tolerogenic factors are co-injected, resulting in uptake and subsequent tolerogenic presentation of auto-antigens by antigen presenting cells. This technology has shown to prevent diabetic onset in 60% of animals in the NOD mouse model of T1D, and has successfully completed the first stage of the FDA mandated two-species pre-clinical safety studies.
Our second technology consists of phagocytosable MPs containing auto-antigen embedded in a self-assembling hydrogel matrix loaded with tolerogenic agents, allowing for uptake and subsequent tolerogenic presentation of auto-antigens by antigen presenting cells Subcutaneous administration of this technology prevents diabetic onset in an impressive 80% of animals in the NOD mouse model of T1D. A recently awarded Phase 1 SBIR grant from the NIH is allowing us to evaluate the pre-clinical safety of this exciting technology.
Our final technology covalently links nanoparticles loaded with auto-antigen and tolerance inducing factors to regulatory T Cells (Tregs). Re-introduction of modified Tregs results in the induction of a tolerogenic microenvironment, allowing for antigen presenting cells to present the auto-antigen in a tolerogenic manner. This promising technology is still in the development stage and efficacy is currently being evaluated thanks to a recently awarded Phase 1 SBIR grant and an Exploratory/Developmental Research grant (R21) from the NIH.